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Abstract
Like other body districts, lungs present a complex bacteria community. An emerging function of lung microbiota is to pro-
mote and maintain a state of immune tolerance, to prevent uncontrolled and not desirable inflammatory response caused by 
inhalation of harmless environmental stimuli. This effect is mediated by a continuous dialog between commensal bacteria 
and immune cells resident in lungs, which express a repertoire of sensors able to detect microorganisms. The same recep-
tors are also involved in the recognition of pathogens and in mounting a proper immune response. Due to its important role 
in preserving lung homeostasis, the lung microbiota can be also considered a mirror of lung health status. Indeed, several 
studies indicate that lung bacterial composition drastically changes during the occurrence of pulmonary pathologies, such 
as lung cancer, and the available data suggest that the modifications of lung microbiota can be part of the etiology of tumors 
in lungs and can influence their progression and response to therapy. These results provide the scientific rationale to ana-
lyze lung microbiota composition as biomarker for lung cancer and to consider lung microbiota a new potential target for 
therapeutic intervention to reprogram the antitumor immune microenvironment. In the present review, we discussed about 
the role of lung microbiota in lung physiology and summarized the most relevant data about the relationship between lung 
microbiota and cancer.
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Introduction
The human body is colonized by bacteria and other microor-
ganisms that maintain a symbiotic relationship with the host, 
creating an ecological community defined as microbiota. In 
the last few years, the importance of microbiota in partici-
pating in different aspects of human physiology is emerg-
ing. Bacteria inhabiting the intestine are reported to play 
crucial roles in the digestion of different types of nutrients, 
in the production of vitamins and other metabolites and, 
most importantly, in regulating the immune homeostasis. 
However, other organs possess their own micriobiota, such 
as lungs [1].
The discovery of lung microbiota was delayed by the 
long-held view that the lungs of healthy individuals were 
sterile and by technical difficulties in collecting samples for 
the analysis [2]. The new technologies, based on the high-
throughput sequencing of the 16S rRNA gene, significantly 
revolutionized our knowledge in the field. Indeed, one of the 
first published studies that utilized those genomic techniques 
finally proved that lungs harbor a wide range of different 
microbial species that are important in keeping the lungs in 
a good health status [3].
In the present review, we summarized the most important 
data available about the lung microbiota mainly focusing on 
the connections between lung microbiota and cancer.
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Lung microbiota: development 
and composition in healthy lungs
Lungs are lined by a thin mucus layer with bacteriostatic 
properties that represents a low-nutrient environment for 
microbes. Lung microbiota are constituted by approxi-
mately 2.2 × 103 bacterial genomes per  cm2 and their com-
position depends on three ecological factors: immigration, 
elimination, and the effects of local growth conditions on 
the replication rates of community members. Microbiota 
modifications can be determined by the perturbations in 
one or more of these factors. At the steady state, the micro-
bial community balance is the result of a dynamic equilib-
rium maintained by immigration, through microaspiration, 
and elimination, via cough, mucociliary clearance, and 
immune system activity. The type and number of microbial 
species present in the lungs are not homogeneous along 
the airways, but are influenced by the anatomical site and 
by local environmental conditions. Factors that impact on 
commensal bacteria growth and survival, include those 
common to all microbial ecological niches present in the 
human body, such as nutrients availability, temperature, 
pH, oxygen tension, as well as the abundance and activa-
tion state of host immune cells. In healthy lungs, the envi-
ronment is generally inhospitable for bacterial community 
development, resulting in relatively low bacterial replica-
tion rate. The microbial community is continually renewed 
and replaced, but the majority of microbes involved in 
these processes belongs to four phyla: Bacteroidetes, Fir-
micutes, Proteobacteria, and Actinobacteria. In healthy 
humans, Prevotella, Streptococcus, Veilonella, Neisseria, 
Haemophilus, and Fusobacterium are the most abundant 
genera in the lungs [2-4].
However, during the occurrence of a lung pathology, 
the local growth conditions change dramatically, creat-
ing permissive niches for the growth of specific bacterial 
species that are able to adapt to a specific environmental 
conditions of the altered respiratory tract. The adaptation 
to a peculiar lung environment confers to these microbes 
an advantage that overwhelms the influence of immigra-
tion and elimination processes on the respiratory ecosys-
tem [5].
Lung microbiota and pulmonary immune 
tolerance
Although, the lung immune cells have to patrol the airways 
to counteract the spread of pathogens, one of their most 
important duties is to avoid exaggerated and unwanted 
inflammatory responses to harmless environmental stimuli. 
Indeed, the lung microenvironment is characterized by 
high immune “tolerance” that is primarily maintained by 
subpopulations of alveolar macrophages (AMs) and den-
dritic cells (DCs) [6]. These cells exert their immunoregu-
latory properties by inducing the generation of regulatory 
T cells (Treg) [7] and by the release of prostaglandin E2 
 (PGE2), tumor growth factor-beta (TGF-β) and interleu-
kin-10 (IL-10) [6]. Increasing evidences indicate that lung 
microbiota, acting on resident immune cells, have a key 
role in promoting immune tolerance in lungs.
Interaction of lung microbiota with local immune 
cells
Lung immune cells, especially antigen-presenting cells 
(APCs, i.e., AMs and DCs), and airway epithelial cells are 
equipped with sensors, the so-called pattern recognition 
receptors (PRRs), able to recognize molecules of host and 
microbial origin. PRRs comprise different types of recep-
tors, such as Toll-like receptors (TLRs), NOD-like receptors 
(NLRs), C-type lectin receptors (CLRs) and protease-acti-
vated receptors (PARs), whose activation, upon engagement 
by their own specific ligands, induces the expression of 
immune-related genes encoding for inflammatory cytokines, 
type I interferons, and antimicrobial peptides. Their activa-
tion promotes the initiation of innate and adaptive immune 
response against pathogens [8, 9].
The fact that PRR ligands are shared by both commen-
sals and pathogens raises the question about the ability of 
lung immune system to promptly respond to an incoming 
infection. All innate immune sensors are able to distin-
guish between danger signals, leading to the production of 
pro-inflammatory mediators, and safety signals, molecules 
released by not-damaged tissues, dietary components and 
commensal microbiota [10]. The discrimination between 
signals originating from “bad” or “good” bacteria can be 
achieved through different ways. These mechanisms have 
been well investigated in the gut, but it is reasonable to 
speculate that a similar situation can also occur in the lungs.
Aside from the fact that microbiota can act as a mecha-
nism of defense itself preventing the growth and spread of 
potential harmful microorganisms and, therefore, avoiding 
their recognition by the immune system [11], the simplest 
method to achieve tolerance can be defined as “tolerance by 
exclusion”, since commensal bacteria are largely excluded 
from the lining epithelium [12, 13]. Due to the presence 
of mucus, the microbiota, lacking the ability to completely 
pass through this protective layer, cannot reach the epithe-
lium and therefore cannot be sensed by epithelial PRRs [13]. 
On the contrary, pathogenic bacteria that possess the so-
called virulence factors can easily breach the mucus layer 
and disseminate through the epithelium and the underlying 
tissues causing the initiation of an inflammatory response 
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[13, 14]. Moreover, to avoid the recognition of commensal 
microbes by PRRs, these receptors are not randomly distrib-
uted along the mucosal surface, but their expression is stra-
tegically compartmentalized in well-defined areas, usually 
inaccessible to commensal bacteria [15-18]. The restricted 
expression of PRRs reinforces the “tolerance by exclusion”. 
In this scenario, the lack of a cross talk between commensal 
bacteria and PRRs seems to be a prerequisite to maintain 
intestinal homeostasis, but more recent data challenge this 
view. Indeed, a growing body of evidence suggests that, in 
normal conditions, a persistent PRR activation triggered by 
microbiota-derived signals is essential to preserve the epi-
thelial barrier integrity [19-21]. Therefore, further inves-
tigations are needed to fully understand the role of PRRs 
in governing mucosal regulatory mechanisms. As already 
mentioned, PRRs signaling is necessary to promote an 
adequate innate and, eventually, adaptive immune response 
against invading pathogens, but, in “steady-state” condi-
tions, this signaling is generally suppressed or mitigated to 
prevent potentially detrimental chronic inflammation. For 
this reason, PRRs expressed by epithelial cells and immune 
cells populating the mucosal interfaces are hyporesponsive 
to their own cognate ligand stimulation, and PRR hypore-
sponsiveness is the result of the combination of different 
factors [22, 23]. First, the epithelium and immune cells 
at the mucosal interface have been found positive for the 
expression of proteins involved in dampening PRR signaling 
pathways, so that these cells can finely tune the response to 
PRR stimulation depending on the stimulus received [22, 
23]. Second, after PRR recognition, PRR receptors establish 
various forms of cooperation with other innate receptors and 
the nature of these interactions can influence the specificity 
for a particular ligand and the downstream signaling path-
way promoting different cellular response, another way to 
discriminate between safety and danger signals. Moreover, 
the final outcome of PRR receptor signals depends also on 
the milieu of cytokines and other soluble factors that can 
shape the immune cell reaction to a specific PRR agonist 
[10]. For example, the immunoregulatory cytokine IL-10, 
secreted by immune cells, is able to counteract PRR activa-
tion [24].
In addition to mechanisms that the human body has 
developed to maintain tolerance toward commensals, it is 
worth highlighting that also the microbiota co-evolved with 
humans implementing several stratagems to avoid immune 
recognition. It has been reported that, due to peculiar modi-
fications of their chemical composition, signals derived from 
commensal microbes are less agonistic to PRR compared 
to those from pathogens [13, 25, 26]. However, it is very 
unlikely that a microorganism may be recognized on the 
basis of only one PRR ligand. It is plausible to hypothesize 
that the “good or bad” bacteria discrimination is based on a 
plethora of signals recognized by different combination of 
PRRs, creating a signature that identifies, in a unique way, 
a specific bacteria.
With particular regard to lung environment, it is emerg-
ing that the cross talk between microbiota-derived PRR 
ligands and airway resident immune cells may represent an 
important factor to sustain a certain grade of immunosup-
pression. For instance, TLR tolerance is achieved after per-
sistent TLRs stimulation, implying that previous exposure 
to a TLR ligand decreases the inflammatory responses to a 
second challenge with the same ligand or with another one 
[27-29]. In healthy lungs, APCs and epithelial cells are con-
tinuously exposed to these ligands and it is now well known 
that repeated or chronic exposure to endotoxins causes 
macrophage, dendritic cells and epithelial cells to acquire 
a tolerogenic phenotype [30-33].
Moreover, the contribution of microbial stimuli, through 
PRR receptor stimulation, in maintaining the immune tol-
erance in lungs is also testified by the fact that lung DCs 
primed by TLR ligands are able to induce class-switch 
recombination in B cells, promoting the generation of 
plasma cells producing IgA, which are a subclass of immu-
noglobulins recognized to induce a tolerizing phenotype at 
mucosal surfaces [34]. Collectively, the available data point 
to a role of lung microbiota in the creation of an immune-
tolerant environment.
Evidences of the essential role of lung microbiota 
in pulmonary immune tolerance
Among the human body non-sterile tracts, the presence 
of commensal bacteria is essential to maintain homeosta-
sis and, in general, a good health status. To avoid chronic 
inflammation under normal condition, microbiota partici-
pate in shaping an immune-tolerant environment especially 
through the development, activation and recruitment of 
immune cells with immune-regulatory activity such as Treg, 
M2-polarized macrophages and tolerogenic DCs. Although 
this important role played by commensal bacteria is widely 
described in the context of intestinal immunity, today there 
are also some insights regarding lung immune contexture 
[35].
Indeed, lung microbiota have been recently thought to 
play a role in the immune tolerance influencing the recruit-
ment and activation of APCs and Tregs. This hypothesis is 
supported by multiple lines of evidence both in mice and in 
humans. In mice, Gollwitzer et al. have demonstrated that 
the appearance of specific bacterial taxa after birth is nec-
essary for the development of Tregs [36]. Immediately after 
birth, newborn mice were susceptible to develop excessive 
airway eosinophilia, accompanied by the release of T-helper 
two  (Th2) cytokines and airway hyper-responsiveness after 
exposure to house dust mite allergens, although their lungs 
had great quantities of  CD4+Foxp3+CD25+Helios+Treg cells. 
 M. Sommariva et al.
1 3
During the first 2 weeks after birth, the bacterial load in the 
lungs increases, paralleled by a progressive shift of bacterial 
phyla from a prevalence of Gammaproteobacteria and Fir-
micutes toward Bacteroidetes. The modifications of micro-
biota composition determine a decreased responsiveness 
to aeroallergen due to the appearance of Helios–Treg cell 
subset that exerts potent immunosuppressive activity. The 
development of this population depends on the increased 
expression of programmed death-ligand-1 (PD-L1) on DCs, 
induced by the changes of lung commensal community. Lack 
of microbial colonization or PD-L1 blockade during the first 
2 weeks after birth caused an excessive sensitivity to aller-
gens that continued until adulthood. Adoptive transfer of 
Treg cells from adult mice to newborn animals, before aeroal-
lergen exposure, reversed hypersensitivity [36]. Moreover, 
it has been reported that germ-free (GF) mice sensitized 
and challenged with ovalbumin have an increased airway 
hyper-reactivity and inflammation compared to specific 
pathogen-free (SPF) mice and that the increased reactivity 
is reduced after reconstitution with commensal bacteria [37]. 
This study revealed that the immune dysregulation in GF 
mice was associated with alterations in plasmacytoid DCs 
(pDCs) and AMs development and function in the absence 
of commensals. Therefore, the commensal flora “educates” 
lung immune cells, shaping them toward a  Th2-prone activa-
tion state. The observation that exaggerated allergic airway 
inflammation can be reverted by the reconstitution of GF 
mice with lung commensals obtained from wild-type mice 
may represent the rationale for the development of new pos-
sible therapeutic strategies in the treatment of allergic airway 
inflammation [37].
Moreover, Wang et al. demonstrated that SPF mice are 
more sensitive to death induced by acute inflammation after 
influenza virus challenge than mice living in a natural envi-
ronment. The authors demonstrated that the presence of 
commensal Staphylococcus aureus, commonly colonizing 
the upper respiratory tract (URT), is essential for resistance 
to lethal inflammatory response [38]. The mechanism under-
lying the protective effect mediated by S. aureus relies in the 
recruitment of  CCR2+CD11b+ monocytes from the blood-
stream into the alveoli and the subsequent maturation and 
polarization to M2 AMs in a TLR2 pathway-dependent man-
ner. Indeed, TLR2 deficiency or AM depletion abrogates this 
protection. In turn, M2 AMs suppress influenza-mediated 
lethal inflammation through the release of anti-inflammatory 
molecules and the expression of immunomodulatory ligands 
[38]. This work opened a new and intriguing scenario in 
which the airway microbiota acts as defender against influ-
enza-mediated lethal inflammation.
As described, most of the data presented relies on the 
use of GF mice. This preclinical model has the undoubted 
advantage of allowing the dissection of the immunological 
effect exerted by one or more bacteria. However, it should 
be noted that these mice carry intrinsic biases that might 
represent confounding factors during the interpretation 
of the results. Although it has been demonstrated that GF 
mice have a similar level of B and T cells, conventional and 
 CD103+ DCs and pDCs compared to normal mice [36, 39], 
the lack of microbiota interferes with the correct develop-
ment of the immune system [36, 37]. Therefore, in these 
mice the immune system is quite immature, and the intro-
duction of bacteria may induce an immune response that 
it is not superimposable with a “physiologic” inflamma-
tory response [40, 41]. Alterations in the immune response 
in these mice are also testified by the fact that they do not 
respond to different types of immunotherapy [42, 43].
The ability of lung microbiota to mitigate the inflamma-
tory response was also observed in humans. Indeed, AMs 
isolated from healthy subjects, divided into two different 
groups (pneumotypes) according to lung microbiota com-
position, responded differently to TLR4 ligation. Particu-
larly, the presence of high bacterial load and predominant 
taxa derived from URT was associated with an attenuated 
immune response of AMs to lipopolysaccharide (LPS). 
This result indicated a role of microbiota in regulating the 
inflammatory response at the pulmonary mucosal surface 
[44]. Other studies in humans indicate that the presence 
of members of the Bacteroidetes phylum decreases lung 
inflammation [45], while Prevotella spp. and Veillonella 
spp. increase T-helper 17  (Th17) cell-mediated lung inflam-
mation [44]. Studying a cohort of patients affected by HIV 
and pneumonia, Shenoy et al. were able to classify patients 
into distinct groups based on similarities of airway micro-
biome composition and demonstrated that a specific micro-
biome was associated with a down-regulation of T-helper 
1  (Th1) proinflammatory responses and chronic viral infec-
tion [46]. All these studies indicate that commensal micro-
organisms that colonize the respiratory tract are critical in 
maintaining and sustaining immune “tolerance” in the lung 
microenvironment.
Lung microbiota and cancer
The available data, obtained comparing the lung microbiota 
of healthy subjects versus patients with different lung pathol-
ogies, revealed significant differences in lung commensal 
composition, even in lung cancer patients. As supported 
by different studies, the alpha diversity (the number {rich-
ness} and distribution {evenness} of taxa expected within a 
sample) is generally significantly higher in healthy than in 
tumor lung tissues even if several taxa have been shown to 
be enriched in cancer specimens. For instance, by analyzing 
210 bronchoscopic samples, Laroumagne et al. identified 
Gram-negative bacteria such as Haemophilus influenzae, 
Enterobacter spp. and Escherichia coli, colonizing lung 
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cancer [47], while Hosgood et al. found an enrichment of 
Granulicatella, Abiotrophia and Streptococcus genera in 
oral and sputum samples from lung cancer patients com-
pared to healthy controls [48]. Recently, in a study on sali-
vary samples from 20 lung cancer patients and 10 control 
subjects, the genera Veillonella, Neisseria, Capnocytophaga 
and Selenomonas were reported to be significantly altered 
in patients with squamous cell carcinoma and adenocarci-
noma [49]. This work also showed that the evaluation of the 
presence of both Veillonella and Capnocytophaga might be 
useful as a tool for lung cancer diagnosis [49]. In another 
study, Firmicutes and TM7 phyla and Veilonella and Megas-
phera genera were more abundant in bronchoalveolar lavage 
(BAL) of patients with lung cancer as compared to patients 
with benign diseases [50]. These results point again to the 
utility of the analysis of specific bacteria phyla or genera as 
potential biomarkers for the diagnosis of lung cancer. Fur-
thermore, Streptococcus viridians together with 16 other 
microbial species were higher in lung cancer patients, while 
7 species were specific of healthy controls [51].
Differences in terms of microbiota composition may be 
not restricted to the dicotomy “cancerous versus healthy” 
tissues, but there are also clues that the presence of a grow-
ing tumor can affect the microbiota also in parts of lung 
parenchyma not invaded by neoplastic cells. For instance, 
Liu et al. compared the lung microbiota of paired samples 
from tumor tissues and the contralateral noncancerous sites 
collected from 24 lung cancer patients and samples from 18 
healthy subjects [52]. A significant decrease in microbial 
diversity was observed in patients with lung cancer com-
pared to controls. The genera Streptococcus and Staphylo-
coccus were found significantly more abundant in cancer 
and control subjects, respectively. Interestingly, Staphylo-
coccus and Dialister abundance peaked in healthy samples, 
gradually declined in noncancerous tissue of lung cancer 
patients and reached the lowest presence in tumors. Collec-
tively, these data indicate that microbiota profile profoundly 
changes during carcinogenesis and that tumor cells create for 
themselves a favorable microenvironment also impacting on 
the global lung microbiota by a mechanism not completely 
understood [52]. However, a recently published paper by 
Segal’s group provided some insights about the mechanisms 
through which microbiota can favor cancer cell development 
and growth. They showed that lung cancer patients were 
characterized by an enrichment of the taxa Streptococcus 
and Veillonella in their lower respiratory tract compared to 
the control group. Parallel transcriptomic analysis of bron-
chial epithelial cells revealed an up-regulation of the ERK/
PI3K pathway and in vitro experiments demonstrated that 
Veillonella was able to directly promote the activation of 
ERK/PI3K signaling in airway epithelial cells and in lung 
tumor cells. This pathway is known to represent an early 
event in lung carcinogenesis and, therefore, these findings 
may provide one the first mechanistic explanations about 
how a dysregulated microbiota can influence tumorigenesis 
[53]. The main findings of the presented clinical studies are 
summarized in Table 1.
There are also some evidences of the potential relation-
ship between lung microbiota composition and lung can-
cer prognosis. In particular, Peters et al. in a pilot study, 
performed on paired lung tumor and distal normal samples 
from the same lobe/segment of 19 patients with non-small 
cell lung cancer (NSCLC), showed that higher diversity and 
alteration in lung commensal bacterial composition of the 
unaffected lung tissue was associated with reduced disease-
free (DFS) and recurrence-free (RFS) survival [54]. In the 
same work, greater abundance of Koribacteraceae was 
associated with increased RFS and DFS, whereas greater 
abundance of Bacteroidaceae, Lachnospiraceae and Rumi-
nococcaceae was associated with reduced RFS and DFS) 
[54] (Table 2).
These data point out that bacteria in resected normal lung 
tissue might serve as biomarkers to predict disease recur-
rence risk in early-stage NSCLC. If the prognostic value of 
lung microbiota composition is validated in future studies, it 
will also represent a novel target for therapeutic intervention 
to improve RFS in lung cancer patients (Table 2).
An association between the presence of specific bacte-
ria and clinical outcome has been also reported in a cohort 
of 165 non-malignant lung tissue samples collected from 
Table 1  Microorganisms found in lung cancer patients: clinical studies
Authors Reference Type of sample No. of subjects Findings
Laroumagne S. et al 47 Lung aspirates by bronchoscopy 210 Haemophilus influenzae, Enterobacter spp. and 
Escherichia coli
Hosgood HD III et al 48 Buccal samples and sputum samples 16 Granulicatella, Abiotrophia and Streptococcus
Yan X. et al 49 Saliva samples 86 Capnocytophaga, Selenomonas, Veillonella and 
Neisseria
Lee SH. Et al 50 Bronchoalveolar fluid 28 Phyla: Firmicutes and TM7Genera: Veillonella and 
Megasphaera
Cameron SJS. Et al 51 Spontaneous sputum 10 Streptococcus viridans and 16 other microbial species
Liu HX et al 52 Bronchoscopy samples 42 Streptococcus
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lung cancer patients with different stage disease. The genus 
Thermus was more abundant in tissue from advanced stage 
patients (IIIB, IV), while Legionella was higher in patients 
who developed metastases [55]. Again, the non-malignant 
lung tissue was characterized by higher microbiota alpha 
diversity than the matched tumor tissue, confirming the 
results above reported.
The relationship between the lung microbiota and lung 
cancer has been investigated in different epidemiologic 
studies, and it has been suggested that microbiota altera-
tions may also play an important role not only during tumor 
progression, but also in the response to therapy [56]. How-
ever, most of the published data on the impact of microbiota 
in regulating the efficacy of different types of drugs were 
obtained studying bacteria in the gut [57] and, to the best of 
our knowledge, there are no reports regarding lung micro-
biota. However, since many anticancer agents are systemi-
cally administered, they can easily reach the lung environ-
ment through the bloodstream and, here, can be uptaken by 
commensal bacteria and chemically modified. Although the 
metabolism of lung microbiota is far from being understood, 
few data suggest that microorganisms inhabiting the lung 
may possess metabolic activity themselves. For instance, in 
the previously cited paper by Segal et al., the authors found 
that people bearing a microbiota defined as  PneumotypeSPT 
were characterized by a peculiar metabolic profile in lungs 
[44]. Moreover, Cribbs et al. observed metabolomic differ-
ences in BAL obtained from HIV-infected patients compared 
to healthy controls and these differences were ascribed to 
the presence of Caulobacteraceae, Staphylococcaceae and 
Nocardioidaceae in HIV individuals [58, 59]. Therefore, 
bacteria in the lungs might be a metabolically active con-
sortium able to modify the chemical structure of therapeutic 
agents altering their pharmacological activity (in a positive 
or negative way) and/or affecting their effective local con-
centration [60, 61].
Some indications suggest a causal role of specific bacteria 
in promoting cancer development. A significant relationship 
between Mycobacterium tuberculosis (TB) and develop-
ment of lung cancer has been found [62]. A mechanistic 
explanation of this association may be related to a possi-
ble tuberculosis-induced chronic inflammation-associated 
carcinogenesis [62]. The effect of microbiota in inducing 
carcinogenesis probably begins with the ability of micro-
biota and its metabolites to activate TLRs in immune and 
epithelial cells resulting in the initiation of an inflammatory 
processes that, if persistent, can cause irreversible damages 
in normal cells and promote the occurrence of tumors [56].
Another important aspect to be considered is that bacteria 
within the tumor microenvironment influence cancer cell 
growth by exerting immunomodulatory effects.
We previously observed that the aerosol delivery of vari-
ous agents, such as TLR agonists and cytokines, was able 
to favor the immune-mediated control of experimental lung 
metastases, indicating the feasibility of influencing local 
lung immunity through a non-invasive strategy [63-67].
Based on this evidence, we recently reported that the 
commensal lung microbiota can be in vivo manipulated by 
aerosolized antibiotics. This treatment, decreasing the per-
centage and activity of  Tregs and, at the same time, activating 
immune effector cells, enhanced immunosurveillance in the 
lung and reduced the growth of B16 melanoma lung metas-
tases [68].  Tregs reduction was associated with a decrease of 
abundance of the genus Streptococcus and the concomitant 
expansion of generally less represented genera of Proteo-
bacteria and Actinobacteria [68]. Moreover, we also dem-
onstrated that aerosolized Lactobacillus rhamnosus promote 
immunosurveillance against melanoma metastases by induc-
ing the maturation of resident pulmonary APCs and reduc-
ing the M2 polarization of alveolar macrophages [68]. Thus, 
the two different strategies to modify the lung microbiota by 
aerosolizing antibiotics or probiotics, promote an anti-tumor 
activity with different immune mechanisms are: antibiotics 
activate antitumor effector cells by inducing a pauperiza-
tion of microbial signals necessary for the recruitment of 
Tregs in the lung, while probiotics appear to overcome the 
commensal bacteria-induced tolerance promoting the matu-
ration of resident APCs [68]. Moreover, besides playing an 
antitumor effect through the modulation of microbiota, some 
antibiotics, as macrolides, also exert pharmacological effects 
directly on tumor cells, particularly reducing pro-inflamma-
tory cytokines release and inhibiting autophagy and angio-
genesis [69]. In a study on NSCLC patients, indeed, claryth-
romicin treatment was associated with an increased survival 
Table 2  Association between lung microbiota and lung cancer prognosis
RFS recurrence-free survival, DFS disease-free survival
Authors Reference Type of sample No. of subjects Findings
Peters HA et al 54 Lung cancer and matching 
normal lung tissues
19 Koribacteraceae associated with increased RFS and DFS
Bacteroidaceae, Lachnospiraceae, and Ruminococcaceae 
associated with reduced RFS or DFS
Yu G et al 55 Lung tissue samples 165 Thermus more abundant in advanced stage (IIIB, IV) patients
Legionella higher in patients developing metastases
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time and improved benefit of patients, ascribed to reduced 
IL-6 levels [69]. Thus, this direct antitumor activity of mac-
rolides, by influencing the tumor microenvironment, might 
in turn result in further shaping of the lung microbiota.
In agreement with our results, a recently published paper 
revealed that in a genetic model of lung cancer, antibiotic-
treated or germ-free mice are protected from lung cancer 
development [70]. In that study, a low bacterial burden in 
the lungs (but not in the gut) significantly correlated with 
reduced tumor growth, revealing a clear association between 
local microbiota abundance and lung cancer development. 
The augmented bacterial load and reduced diversity of 
tumor-associated microbiota was accompanied by the 
recruitment of IL-17-producing γδ T cells which, in turn, 
promoted pro-tumoral neutrophil expansion and tumor cell 
proliferation [70]. It should be also noted that the delayed 
tumor growth observed in GF mice may be also ascribed to 
the complete absence of tolerogenic mechanisms in lungs 
[36, 37], such as the presence of cells with immunoregu-
latory activity that could be exploited by cancerous cells 
to avoid immunosurveillance. They also demonstrated that 
intratracheal instillation of a consortium of bacteria isolated 
from late-stage lung tumors accelerated tumor growth and 
that local administration of bacterial products (LPS and pep-
tidoglycan, PGN) robustly stimulated γδ T cells in the lung. 
Similar findings were also obtained in other tumor models 
where, again, a particular microbiota composition was asso-
ciated with the presence in the tumor microenvironment of 
immunosuppressive and pro-tumorigenic immune cells [71].
Collectively, these results represent a strong scientific 
rationale to design new therapeutic strategies able to re-
establish an antitumor immune response to modify the intra-
tumoral microbiota.
It is worth pointing out that, as summarized in this sec-
tion, the majority of the presented data concern the relation-
ship between lung microbiota and lung cancer development 
and progression. Although few reports suggest that lung 
microbiota can affect the efficacy of different anticancer 
drugs, as in the intestine, this field is still at its infancy and 
needs to be further explored.
Lung microbiota, non‑oncology lung diseases 
and cancer
As described for lung cancer, also non-oncologic lung 
pathologies (i.e., chronic obstructive pulmonary disease, 
cystic fibrosis, lung infections, emphysema) can have an 
impact on lung microbiota composition that, although dif-
ferent for each situation, is characterized by loss of bac-
teria abundance and diversity paralleled by an increased 
presence of certain phyla such as Proteobacteria (mostly 
Neisseria, Moraxella and Haemophilus) [72]. For example, 
chronic obstructive pulmonary disease (COPD) is a chronic 
inflammatory disease that causes obstruction of the airways, 
hypersecretion of mucus and a variety of other symptoms 
leading to an impairment of lung parenchyma function [73]. 
Hilty et al. analyzed 43 bronchial lavages obtained from 
healthy individuals and patients with COPD or asthma by 
16S rRNA sequencing and they observed that Proteobac-
teria, in particular Haemophilus spp., were more abundant 
in asthmatics or COPD patients than in healthy individuals. 
On the contrary, Bacteroidetes, mostly Prevotella spp., were 
more frequent in the control group [3]. Moreover, another 
study performed on patients with COPD, smokers with no 
airway disease and healthy subjects revealed the prevalence 
of members of Pseudomonas spp. in COPD patients, while 
Prevotella spp. was, again, more present in the healthy group 
[74]. This scenario is also complicated by the fact that lung 
microbiome differs with the severity of the disease [75-77]. 
A similar situation has been also described for cystic fibrosis 
[72]. Since many lung disorders represent a risk factor for 
the development of lung cancer [78] and all of these diseases 
shared the characteristic of an altered lung microbiota [72], 
it is highly plausible that these changes may represent one 
of the possible causes of tumorigenesis. This is particularly 
clear in the context of Mycobacterium tuberculosis infec-
tion, which determines chronic inflammation and lung tis-
sue fibrosis correlated with lung cancer onset [62]. Chronic 
inflammation in the lungs can be also caused by other 
bacteria such as Haemophilus, Moraxella, Streptococcus, 
Staphylococcus and Pseudomonas [79]. On the other hand, 
the pattern of bacteria characterizing lung cancer patients 
and subjects with other lung diseases is different [80], sug-
gesting that lung dysbiosis can induce chronic inflammatory 
status that, in turn, may trigger and sustain cancerogenesis. 
Subsequently, the presence of a growing tumor may further 
shape lung microbiota composition.
Lung microbiota, smoke and cancer
Cigarette smoke is one of the main causes of morbidity and 
mortality all over the world and it is associated with dif-
ferent types of lung disease, especially lung cancer [81]. 
Smoking has a profound impact on upper airway microbi-
ota, but it appears that it cannot have the same effect on the 
lower respiratory tract bacteria composition. Indeed, Morris 
et al. analyzed 64 bronchoscopic alveolar lavages collected 
from non-smokers and smokers and they found differences 
between the two cohorts only in mouth bacteria communi-
ties but not in lungs [82]. Moreover, Munck et al. reported 
the lack of important changes in bacterial diversity after 
smoking cessation [83], indicating that smoking does not 
have a key role in determining modifications in lung com-
mensal composition. On the other hand, studies performed 
in humans [74] and mice [84] suggested that smoke expo-
sure can alter bacterial composition in the lower respiratory 
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tract, probably by impairing local immune cell activity. 
Since chemical compounds present in the tobacco smoke 
may affect lung immune cells function [85, 86], smoking 
may determine a disequilibrium in the microbiota–immune 
cell cross talk, leading to dysbiosis, chronic infection and, 
eventually, lung cancer.
Implications and perspectives
Although the resident lung microbiota has been described 
only recently, its association with lung cancer development 
is clearly emerging. The data regarding a link between lung 
microbiota and lung cancer development open a key ques-
tion that remains to be answered: “can lung microbiota be 
the cause or the consequence of lung cancer development?” 
Based on the available data, it is not possible to draw any 
final conclusion but some clues allow us, at least, to specu-
late. First, the colonization of lungs with particular micro-
bial species can be causally related to chronic inflammation 
and lung carcinogenesis. In normal conditions, it seems that 
lung microbiota is involved in promoting immunesuppres-
sive cell accumulation to prevent unwanted inflammatory 
reactions to harmless stimuli. On the other hand, patients 
with pulmonary diseases, reported to be risk factors for lung 
cancer, have a microbiota that profoundly differs from that of 
healthy lungs that, indeed, determines a chronic inflamma-
tory status. In this scenario, particular strains of bacteria may 
alter the physiologic immunotolerant environment by “repro-
gramming” resident immune cells, for example through the 
release of particular metabolites with immunoregulatory 
properties, or by recruiting inflammatory immune cells from 
the bloodstream. Second, it is also true that tumor cells can 
modify lung environment and these alterations may, in turn, 
impact on lung microbiota composition. Future studies will 
answer this question and reveal whether the lung microbi-
ome can be manipulated therapeutically to influence disease 
progression and the response to therapy.
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